Zoetis Slashes 2026 Guidance by 10%, U.S. Pet Sales Plunge 11%
ZTS is trading near its 52-week low of $71.47 (6.7% above the low).
Summary
Zoetis missed Q2 revenue estimates and cut full-year 2026 adjusted EPS guidance by roughly 10% at the midpoint, now $6.15–$6.25 versus prior $6.85–$7.00. U.S. companion animal sales fell 11% on lower clinic visits and price sensitivity, with dermatology and Simparica Trio under competitive pressure. The company also announced a CFO/COO transition, with James Saccaro taking over from Wetteny Joseph. This follows the 8-K and 10-Q filed earlier today, adding management commentary and segment detail. The stock rose 3.8% on the day, possibly reflecting relief that the reset was not worse, but the fundamental picture is deteriorating.
At the time of this announcement, ZTS was trading at $76.28 on NYSE in the Life Sciences sector, with a market capitalization of approximately $32B. The 52-week trading range was $71.47 to $160.48. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.